Galmed & Tissue Dynamics Unveil New Cardiac Fibrosis Pathway, Advance Aramchol Towards IND
GLMD sits 85% above its 52-week low of $0.411 on light trading volume (0.1× avg).
Summary
Galmed Pharmaceuticals announced positive preclinical results from its collaboration with Tissue Dynamics, identifying a new metabolic pathway for cardiac fibrosis and demonstrating Aramchol's efficacy in human cardiac organoids, leading to a new patent filing and plans for IND-enabling activities.
Key Events · Product Development and Regulatory · GLMD
-
New Metabolic Pathway Discovered
Galmed and Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis and heart failure using human cardiac organoid models.
-
Aramchol Combination Efficacy
A combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately 4-fold (p<0.001) in inflammatory human cardiac organoids, while preserving cardiac muscle integrity.
-
Pipeline Advancement for Cardiac Fibrosis
Based on these preclinical findings, a new patent application has been filed, and preparations are underway to support future IND-enabling activities for Aramchol in cardiac fibrosis.
Analysis · GLMD · Life Sciences
This filing announces significant preclinical results from Galmed's collaboration with Tissue Dynamics, identifying a previously unrecognized metabolic pathway for cardiac fibrosis and heart failure. The study demonstrated that a combination of Galmed's lead compound, Aramchol Meglumine, and a PPARα agonist reduced fibrotic burden by approximately four-fold in human cardiac organoids. This discovery, coupled with a new patent application and plans for IND-enabling activities, represents a material advancement for Galmed's pipeline diversification into cardiometabolic indications, potentially opening a new therapeutic avenue for Aramchol.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GLMD was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $0.41 to $2.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.